Is ARA-290 safe?
Emerging ResearchSide effects, risks, and safety considerations based on available research.
Research status
ARA-290 has some clinical data but research is still developing. Safety data exists but may come from small studies, short-term trials, or specific populations that may not reflect your situation.
Known concerns & side effects
- ⚠not FDA or EMA approved — clinical trials ongoing
- ⚠Phase 2 data promising but Phase 3 trials needed
- ⚠only available in clinical trial or experimental settings; no commercial product
- ⚠sarcoidosis is a niche indication — efficacy in common peripheral neuropathy types less established
Use caution with
See all 1 studies on the full ARA-290 profile.
Frequently asked questions
Is ARA-290 related to EPO doping?
No. ARA-290 specifically does not stimulate erythropoiesis. It was engineered to avoid this entirely, targeting only the tissue-protective IRR receptor. It would have no performance-enhancing effect on oxygen transport and is not on the WADA prohibited list. The connection to EPO is purely structural and mechanistic.
Can I obtain ARA-290 outside a clinical trial?
Not legitimately. ARA-290 (Cibinetide) is a clinical-stage drug without any approved indication. It is not available as a research peptide through standard channels in a well-characterized pharmaceutical form.
Full ARA-290 Profile
Evidence, timeline, products & more
Take the Peptide Quiz
Get personalized recommendations
Last updated: 2026-06-10
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.